Diabetic Gastroparesis Treatment Market 2025 | Market Growth, Personalized Therapy Trends, Telemedicine & Microbiome Integration

Diabetic Gastroparesis Treatment Market reached US$ 3.1 billion in 2022 and is expected to reach US$ 4.2 billion by 2030 growing with a CAGR of 3.8% during the forecast period 2023-2030, according to DataM Intelligence research report" as per DataM intelligence research report.

Diabetic Gastroparesis Treatment Market: Recent Industry Developments
United States
✅ In 2025, A multicenter Phase III randomized trial of relamorelin (RM-131), a ghrelin receptor agonist, is actively underway in diabetic gastroparesis.This builds on positive Phase II findings showing reduced symptoms and accelerated gastric emptying.It represents the most advanced pipeline candidate in this disease area.

✅ In June 2020, Evoke Pharma began commercial manufacturing of Gimoti, an FDA-approved nasal spray for diabetic gastroparesis, after approval in June 2020.This non-oral prokinetic expanded administration options for patients.It marked a novel route to address acute and recurrent symptoms.

✅ In December 2016, The FDA granted Fast Track designation to velusetrag, a selective 5-HT4 receptor agonist, for diabetic (and idiopathic) gastroparesis.This facilitated accelerated development for a promising oral prokinetic candidate. Subsequent Phase II data showed improved gastric emptying versus placebo.

Japan
✅ In 2025, Japan is tracking global innovation with multiple pipeline agents including relamorelin, prucalopride, and velusetrag playing out in international clinical development.Japanese clinicians and stakeholders may soon assess these agents' applicability in local practice.This demonstrates Japan's receptiveness to adopting emerging, mechanism-diverse therapies.

✅ In 2025, CinDome Pharma, Evoke Pharma, Vanda, Takeda, and other key players are actively driving pancreatic nervous system-targeted therapies in the global pipeline.While still in development, these activities signal potential future availability in the Japan market.They reflect growing global R&D momentum that could influence Japan's treatment landscape.

✅ In 2025, Japan's diabetic gastroparesis treatment market is currently a niche benefiting from rising interest as emerging therapies progress through global trials. Continued monitoring of clinical data and regulatory developments positions Japanese stakeholders to adopt next-generation treatment options. This readiness underscores prospects for future market activity in Japan.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/diabetic-gastroparesis-treatment-market?jd

Market growth opportunities (2025-2031):

The market is poised to benefit from a growing diabetic population worldwide, which increases the need for effective symptom management. Expanded product innovation such as nasal sprays and novel prokinetic agents is diversifying therapeutic options. Rising geriatric demographics and long-duration diabetes cases are enlarging the at-risk population. Ongoing research into gut microbiome-targeted therapies and precision medicine holds substantial promise. Moreover, expanding distribution networks through hospital, retail, and online pharmacies is improving accessibility across regions.

Diabetic Gastroparesis Treatment Market: Technological Advancements

✦ New nasal delivery systems like metoclopramide nasal spray (e.g., Gimoti) now provide faster relief with improved compliance over traditional oral forms.
✦ Synthetic ghrelin agonists, such as relamorelin, offer enhanced gastric motility by targeting central gut-brain receptors and have received Fast Track designations in clinical development.
✦ Wireless gastric electrical stimulation devices are emerging, enabling less invasive implantation and adaptive stimulation that may improve symptom control.
✦ Advancements in prokinetic and antiemetic pharmacotherapies aim to deliver better efficacy with fewer adverse effects, expanding therapeutic options.
✦ Innovative herbal and microbiome-oriented therapies (e.g., Chinese herbal formulations) are being explored, possibly offering adjunctive treatment routes with reduced side effects.

Diabetic Gastroparesis Treatment Market: Drivers

The surge in global diabetes incidence continues to be a paramount catalyst for diabetic gastroparesis treatment demand. Increased clinical and patient awareness ensures earlier diagnosis and intervention. Advancing therapeutic pipelines from novel delivery systems to innovative molecules are enriching the treatment landscape. Demographic shifts, including ageing populations and high diabetes prevalence in emerging markets, further expand the patient base. Finally, supportive regulatory mechanisms and improved reimbursement, especially for Fast Track therapies, are facilitating the market's expansion.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/diabetic-gastroparesis-treatment-market?jd

Segment Covered in the Diabetic Gastroparesis Treatment Market:

➥ By Type: Grade 2, Grade 3
➥ By Drug Class: Gastroprokinetic Agents, Antiemetic Agents, Anti-histamines, Others
➥ By Route of Administration: Oral, Parenteral, Nasal
➥ By Distribution Channel: Hospitals, Retail Pharmacies, Online Pharmacies

Strategic Players Driving the Diabetic Gastroparesis Treatment Market Forward:

Key players are EVOKE PHARMA, ANI Pharmaceuticals, Inc., Janssen Pharmaceutica N.V, Teva Pharmaceuticals Inc., Pfizer Inc., Salix Pharmaceuticals, Inc., Allergan, Novartis AG, SCHWITZ BIOTECH, Wellona Pharma, and among others.

Why Purchase the Report for Diabetic Gastroparesis Treatment Market?:

➠ Technology & Innovation: Tracks clinical trials and upcoming pharmaceutical advancements to stay ahead in product development.
➠ Market Positioning & Competitive Strategy: Analyzes product performance, market share, and competitor tactics for strategic decision-making.
➠ Real-World Evidence & Physician Insights: Incorporates patient data and physician behavior to align products with actual healthcare needs.
➠ Pricing & Market Access: Reviews reimbursement trends and access models to optimize product pricing and launch strategies.
➠ Regulatory & Industry Shifts: Covers policy changes, health system dynamics, and technology trends impacting market opportunities.
➠ Regional Growth & Expansion: Identifies high-growth markets and investment opportunities for geographic expansion.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=diabetic-gastroparesis-treatment-market

Regional Analysis for Diabetic Gastroparesis Treatment Market:

North America holds a commanding position, bolstered by high diabetes prevalence, favorable reimbursement policies, and robust clinical infrastructure. Europe and Asia-Pacific are also experiencing growth driven in part by rapidly expanding diabetic populations, rising healthcare investments, and growing adoption of innovative therapies.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?jd

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drug Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.